Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system-Reference-Cited by-同舟云学术

Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system

Author:

Liu Ling¹,Zhang Chengyi²,Liu Huihui³,Luo Huan⁴,Cao Rong¹,Xiao Mingxuan⁵,Zou Pan⁶,Xie Zhuzhu¹,Gong Hui²⁷⁸,Ma Rui²⁷⁸,Yan Miao²⁷⁸,Jiang Zhichao⁴

Affiliation:

1. Hunan University of Chinese Medicine, Changsha, China

2. Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China

3. Guangdong Provincial People’s Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital), Zhuhai, China

4. The First Affiliated Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, China

5. China Pharmaceutical University, Nanjing, China

6. Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China

7. International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China

8. Toxicology Counseling Center of Hunan Province (TCCH), Changsha, China

Funder

Natural Science Foundation of Hunan Province

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

Reference26 articles.